Sunil Agarwal - 01 Jun 2022 Form 4 Insider Report for Calithera Biosciences, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2022, 16:05:34 UTC
Prior SEC filing: 08 Mar 2022
Next SEC filing: 20 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Sunil Agarwal

Key filing fact

Sunil Agarwal filed Form 4 for Calithera Biosciences, Inc. on 03 Jun 2022.

Key facts

This page summarizes Sunil Agarwal's Form 4 filing for Calithera Biosciences, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2022, 16:05.

Change

Previous filing in this sequence was filed on 08 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 01 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $0.2000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.